Cost-effectiveness analysis of nab-paclitaxel with or without relacorilant for platinum-resistant ovarian cancer

Platinum-resistant ovarian cancer (PROC) has a poor prognosis and limited treatments. Relacorilant plus nab-paclitaxel (RnP) shows clinical efficacy in Phase III trials, but its cost-effectiveness has not yet been evaluated. This study evaluated RnP versus nab-paclitaxel (nP) for PROC from the U.S. payers’ perspective. A partitioned survival model (1-month cycle, 5-year time horizon) was utilized to assess the cost-effectiveness of the RnP regimen for PROC, and appropriate parametric functions w